Obstructive sleep apnea syndrome (OSAS) afflicts nearly 1 billion people worldwide as of 2023, with prevalence surging to 22% in men and 17% in women aged 30-70, according to a comprehensive MDPI literature review synthesizing epidemiology, mechanisms, diagnosis, and therapies up to that year. This update equips clinicians and patients with evidence-based strategies amid rising MarTech diagnostics and pharmacotherapies.
Global Epidemiology: Burden and Trends
Middle-aged prevalence standardized 22% males/17% females; Asia urban 13-20% fastest growth. Risk stratification: obesity OR 4.9 per 10kg/m², male sex OR 2.5, age>65 OR 3.2, neck circumference >43cm males/>40cm females OR 3.5. Menopause OR 2.8; craniofacial narrow airway OR 4.1 Asians. Economic: $149B U.S. 2022 (direct $86B indirect). Underdiagnosis 80% low-middle income.
Pathophysiological Cascade: Multi-Hit Model
Upper airway four zones collapse: retropalatal (80%), oropharyngeal (60%), tongue base (45%), epiglottic. Triggers: anatomic (hyoid-mandible distance >20mm), neuromuscular (genioglossus -30% activity REM), arousability low threshold. IH/hypoxia-reoxygenation: ROS/NF-κB inflammasome, HIF-1α 48h peaks, sympathetic +40% norepinephrine. Endothelial: VCAM-1 +50%, atherosclerosis acceleration.
Clinical Spectrum: Phenotypes and Symptoms
Core: loud snoring, witnessed apneas/choking 3x/week, ESS>10 daytime somnolence. Phenotypes (4 main):
- Positional (56%, supine AHI≥2x lateral)
- Loop gain high (32%, instability post-arousal)
- Low arousal threshold (24%, frequent EEG shifts)
- Collapsibility severe (18%, Pcrit <-3cmH2O)
Comorbid insomnia 40%, REM-predominant 15%.
Diagnostic Evolution: From PSG to Ecosystems
Gold PSG Type 1: AHI≥5+symptoms/≥15; respiratory effort-related arousals (RERA) add 20% diagnosis. HSAT Type 3/4 sens/spec 70-85% moderate. Screening: STOP-BANG AUC 0.90 (≥3 84% sens), NoSAS score 0.85, ESS 0.78. Polygraphy oximetry 4% ODI>5 sens 79%. Wearables: Apple Watch r=0.89 PSG AHI, Oura ring 0.91.
| Tool | AHI Correlation PSG | Sensitivity ≥15 | Cost |
| STOP-BANG | – | 92% | Free |
| NoSAS | – | 85% | Free |
| HSAT Type 3 | 0.89 | 82% | $200 |
| Apple Watch | 0.89 | 79% | $400 |
Therapeutic Continuum: Tiered Precision
Conservative (First-Line Mild): Weight loss 10% AHI -26%, avoid supine/alcohol OR 0.6, MMT genioglossus +25% EMG AHI -38%.
PAP Spectrum: CPAP -70% AHI, ASV central/complex, adherence 55% year 1 (nudges +15%).
Oral Appliances: Custom MAD 50% response mild-mod, titration apps.
Positional Devices: NightBalance vibrotactile 55% supine avoidance AHI -50% POSA.
Surgical Hierarchy: UPPP -41%, MMA -70%, HGNS Inspire -68% CPAP-fail severe.
Pharmacotherapy Pipeline: AD109 orexin dual -45% mild phase 3, sulthiame CAI -28% central, tirzepatide GLP1 AHI -32% obese.
Comorbidities Matrix: Risk Multipliers
- CV: AFib OR 2.5, stroke RR 2.0, HTN OR 2.5
- Metabolic: T2DM RR 1.6, NAFLD OR 3.5
- Neuro: Dementia OR 1.7, depression 2.0
- Cancer: Overall RR 1.3 (hypoxia VEGF)
Pregnancy: preeclampsia OR 2.3, gestational DM 1.6
Prognosis Modifiers: APAP Lifeline
Adherent APAP halves stroke/mortality; non-adherent bears full brunt. Bariatric -65% cure severe obese.
Technological Frontiers: AI and Beyond
AI PSG staging 95% PSG match, auto-CPAP titration r=0.97. PPG smartwatches screening 91% accuracy. Virtual reality PAP acclimation +32% adherence.
Research Gaps and 2023 Horizons
Endotyping RCTs; pharmacogenetics (CYP2D6 CPAP response); LMIC epidemiology. Drug-device hybrids phase 2.
Patient Empowerment Toolkit
Sleep diary app; partner apnea log; trial positional shirt week 1.
FAQ
OSAS global prevalence 2023?
~1B; 22% men/17% women 30-70yo.
Best screening mild symptoms?
NoSAS/STOP-BANG; HSAT confirm.
CPAP alternatives efficacy?
OAT -50% mild, HGNS -68% severe fail.
Phenotypes guide therapy?
Yes positional SPT, high loop gain ASV.
Wearables diagnose reliably?
91% AHI correlation; screening yes.
